Lead: In December 2024, 42-year-old Ameilia Boodoosingh Gopie—who had struggled with postpartum depression after giving birth in August 2022—missed routine health visits and only pursued care after a shaving cut became infected. A primary care reminder prompted a mammogram that returned abnormal results; additional testing on Christmas Eve confirmed Stage III, triple-positive breast cancer that had spread to nearby lymph nodes. Doctors recommended immediate, aggressive treatment including chemotherapy, surgery and radiation. Gopie and her family moved quickly to a second opinion and began a course of care over the weeks that followed.
Key takeaways
- Ameilia Boodoosingh Gopie, age 42, gave birth in August 2022 and developed postpartum depression that led her to skip routine appointments.
- In December 2024 a primary care visit about an infected shaving cut led to a mammogram; testing on Dec. 24, 2024 confirmed Stage III breast cancer.
- Pathology showed triple-positive disease, a subtype that Cleveland Clinic estimates affects about 10% of breast cancer patients and can be aggressive but often responds to targeted therapies.
- Treatment began immediately: multiple rounds of chemotherapy (with nausea, vomiting and hair loss), a double mastectomy, radiation over three weeks, and ongoing hormone therapy infusions.
- Surgeons found persistent tumor in the breast and cancer in the armpit (lymph nodes), prompting additional chemotherapy and radiation.
- Gopie used short video diaries before treatments and support from family to cope; she is now recovering, has had reconstructive surgery and remains on daily medication and infusions.
Background
Postpartum depression affects a substantial minority of new parents and can disrupt routine self-care, including preventive screenings. In Gopie’s case, the depressive episode after her August 2022 delivery made it difficult to keep medical appointments for many months. Clinicians warn that missed preventive care can delay detection of conditions that are easier to treat when found early.
Breast cancer screening recommendations vary by risk factors such as family history and breast density. Dense breast tissue can mask tumors on mammography and, in some systems, qualifies patients for earlier or supplemental imaging. Triple-positive breast cancers express estrogen, progesterone and HER2 receptors; although that profile allows multiple targeted treatment options, the subtype is often diagnosed at later stages and can be clinically aggressive.
Main event
In December 2024 Gopie went to her primary care physician because of an infected shaving cut. During the visit the doctor emphasized the importance of annual exams and mammograms, noting Gopie’s dense breasts warranted earlier screening. She scheduled imaging, which returned abnormal findings and led to follow-up tests.
On Christmas Eve, Dec. 24, 2024, clinicians delivered the diagnosis: Stage III breast cancer with lymph node involvement. Gopie and her husband sought a second opinion two days later on Dec. 26 and proceeded to plan an accelerated treatment sequence. Multidisciplinary teams including medical oncology, surgical oncology and radiation oncology were engaged.
Pathology characterized the tumor as triple-positive. Her treating radiation oncologist, Dr. Stuart Samuels of the University of Miami Health System’s Sylvester Comprehensive Cancer Center, recommended upfront chemotherapy to reduce tumor burden. Gopie experienced expected chemotherapy side effects—nausea, vomiting, pain and hair loss—and later underwent a double mastectomy when significant residual disease remained.
Surgeons also identified cancer in the axillary lymph nodes, which required additional systemic therapy and a course of radiation over roughly three weeks. Subsequent testing indicated she would need further chemotherapy and ongoing hormone-directed therapies; at the time of the interview she was receiving daily medication and periodic infusion treatments while recovering from reconstructive surgery.
Analysis & implications
Gopie’s case highlights two interrelated issues: the clinical risk of delayed preventive care and the real-world impacts of postpartum mental health on health-seeking behavior. When depression or other barriers cause missed screenings, diagnoses can occur at more advanced stages, limiting options and increasing treatment complexity and morbidity.
Clinically, triple-positive status offers both challenges and therapeutic opportunities. The presence of estrogen, progesterone and HER2 receptors allows use of endocrine therapy, HER2-targeted agents and chemotherapy, which can improve outcomes compared with receptor-negative disease. However, Stage III presentation with nodal spread makes the overall prognosis more guarded and requires multimodal treatment to achieve locoregional control and reduce recurrence risk.
From a systems perspective, Gopie’s experience underscores the value of primary care reminders and care coordination that proactively re-engage patients who have missed preventive visits. Health systems that flag missed screenings—especially for people with dense breasts or other risk markers—may detect disease earlier and reduce downstream treatment burden.
Psychosocially, the episode illustrates the toll on families: partners often assume increased caregiving responsibilities, and patients balance recovery with parenting. Support services—mental health care, social work, and navigation resources—are essential components of comprehensive cancer care and may improve adherence to follow-up and quality of life during treatment.
Comparison & data
| Measure | Gopie’s case | Typical benchmark |
|---|---|---|
| Diagnosis date | Dec. 24, 2024 | N/A |
| Stage | Stage III (node-positive) | Early-stage (I–II) at many screen-detected cases |
| Subtype frequency | Triple-positive (~patient case) | About 10% of breast cancers (Cleveland Clinic) |
| Primary immediate treatments | Chemotherapy, double mastectomy, radiation, hormone therapy | Depends on stage/subtype; early detection can reduce need for multimodality care |
The table situates Gopie’s presentation against typical screening outcomes: screen-detected cancers are more often found at earlier stages (I–II), when single-modality treatments or less extensive surgery may suffice. Triple-positive tumors represent a minority (~10%) of cases but require coordinated systemic and local therapies when diagnosed at Stage III.
Reactions & quotes
“Just saying that C-word ripped me and my husband to pieces,” Gopie recalled, describing the emotional shock when clinicians first used the term cancer on Dec. 24, 2024.
Ameilia Boodoosingh Gopie, patient
“She still has an aggressive cancer, but she’s just living her life,” Dr. Stuart Samuels said, noting the care team’s focus has shifted toward recovery and quality-of-life goals after intensive early treatment.
Dr. Stuart Samuels, radiation oncologist, University of Miami Health System (Sylvester)
Unconfirmed
- Whether an earlier mammogram would have detected Gopie’s tumor at a lower stage cannot be determined retrospectively without prior imaging for comparison.
- Long-term prognosis estimates and recurrence risk remain uncertain until full response to ongoing systemic therapy is assessed over time.
Bottom line
Ameilia Gopie’s experience demonstrates how postpartum mental health challenges can have downstream medical consequences when routine preventive care is interrupted. A timely reminder from a primary care clinician led to imaging that uncovered Stage III, triple-positive breast cancer on Dec. 24, 2024—an advanced diagnosis that required rapid, multimodal treatment.
The case reinforces three practical takeaways: clinicians and health systems should proactively re-engage patients who miss screenings; people with dense breasts or other risk factors may need tailored screening pathways; and integrating mental health and care-navigation services for new parents can help prevent delayed diagnoses. For patients and families facing similar news, multidisciplinary treatment and psychosocial supports are central to recovery and long-term follow-up.
Sources
- CBS News — news report and patient interview
- Cleveland Clinic — clinical overview of breast cancer subtypes and frequency (medical resource)
- University of Miami Health System — Sylvester Comprehensive Cancer Center — treating institution (health system)